DNA methylation inhibits gene expression by preventing transcription factors from binding to DNA. Functioning of nigrostriatal dopaminergic neurons is influenced by the expression of the dopamine transporter (DAT), and genetic variations in the gene encoding DAT contribute to differences in reward processing. We aimed to investigate the action of DAT methylation on DAT protein expression measured by positron emission tomography (PET).
Methods
The emission data were acquired over 90 min with 50 frames after injection of 18F-FP-CIT using PET. Binding potentials (BPNDs) of ventral striatum, caudate nucleus, putamen were measured with the simplified reference tissue method. Genomic DNA was extracted from subjects’ blood sampling. Methylation of 4 regions in SLC6A3 gene was assessed using bisulfite pyrosequencing. The mean percentage of methylation (%) for each cluster was calculated by taking the average of all CpG site methylation levels measured within the cluster. Subjects were assessed with the Generalized Reward and Punishment Expectancy Scales (GRAPES) that consists of 30 items related with the reward and punishment that individuals expect for their behaviors.
Results
Thirty-five healthy males, with an age range between 20 and 30 years, and a mean age of 24.4 ± 2.7 years, were included in this study. The mean percentage of methylation (%) from cluster C showed a trend of positive correlation with DAT availability of ventral striatum (rho = 0.3712, p = 0.0281), not significant after correction for multiple comparisons, and a significant correlation with GRAPES A: reward expectancy scale (rho = 0.7178, p < 0.0001).
Conclusion
DAT methylation from peripheral blood showed a trend of positive correlation with DAT availability of ventral striatum in healthy subjects; however, it was not significant after correction for multiple comparison. The degrees of methylation from cluster C of DAT in peripheral blood were significantly correlated with reward scales of GRAPES A: reward expectancy scale. The association between DAT methylation and DAT expression needs to be investigated further.
Hinweise
Kyoungjune Pak, Ju Won Seok, and Hyun-Yeol Nam contributed equally to this work
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Background
The dopamine transporter (DAT) is a sodium chloride-dependent transmembrane protein on the presynaptic dopaminergic nerve terminal [1], regulating levels of dopamine by reuptake [2, 3]. As DAT binding is correlated with the density of dopaminergic neurons [4], decreased DAT uptake represents dopaminergic neurodegeneration such as PD [4], a neurodegenerative disease with death of dopaminergic neurons in the substantia nigra pars compacta [5, 6]. The most sensitive imaging techniques for the diagnosis of neurodegeneration are positron emission tomography (PET) and single photon emission computed tomography (SPECT) by using ligands that report nigrostriatal dopaminergic function [3], which allow quantifying dopaminergic system in human brain [7].
Epigenetic change is a heritable phenotype change without alterations in the DNA sequence, such as DNA methylation. DNA methylation is an epigenetic process that adds methyl groups to cytosines of the genome, mainly in CpG sites [8]. As DNA methylation inhibits gene expression by preventing transcription factors from binding to DNA [9], DNA methylation is inversely associated with protein expression [10]. Functioning of nigrostriatal dopaminergic neurons is influenced by DAT, and genetic variations in the gene encoding DAT contribute to differences in reward processing [11, 12]. However, in a previous study by Wiers et al., striatal DAT availability measured by 11C-cocaine PET did not show any significant association with DAT methylation of peripheral blood in healthy subjects [13], which is the only report that investigated the association between them. Therefore, we aimed to investigate the action of DAT methylation on DAT protein expression measured by PET and reward scales measured with the Generalized Reward and Punishment Expectancy Scales (GRAPES) [14].
Anzeige
Methods
PET scan
Thirty-five healthy, male subjects without brain injury, neuropsychological disorders were included in this study. The majority of the participants in this study were included in a previous study [15]. An intravenous bolus injection of 18F-FP-CIT was administered. The emission data were acquired over 90 min with 50 frames of progressively increasing durations (15 s × 8 frames, 30 s × 16 frames, 60 s × 10 frames, 240 s × 10 frames, and 300 s × 6 frames) using the Siemens Biograph 40 Truepoint PET/CT (Siemens Healthcare, Knoxville, Tennessee, USA). The dynamic PET data were collected in the 3-dimensional mode, with 148 slices with image sizes of 256 × 256 and pixel sizes of 1.3364 × 1.3364 mm2. These were reconstructed using iterative method with a Gaussian filter.
Image analysis
For a volume-of-interest-based analysis, an averaged image (0–10 minafterinjection) was created from dynamic PET frames and spatially normalized to 15O-Water PET template in statistical parametric mapping 5 (Wellcome Trust Centre for Neuroimaging, United Kingdom). To extract time–activity curves (TACs) of volume of interest from full dynamic PET scans, Oxford-GSK-Imanova striatal atlas (https://fsl.fmrib.ox.ac.uk/fsl) for ventral striatum, caudate nucleus, putamen were applied. DAT availability, expressed in terms of binding potential (BPND), was measured by analyzing TACs with the simplified reference tissue method [16] with the cerebellum as a reference using pmod version 3.6 (PMOD Technologies LLC, Zurich, Switzerland).
DNA extraction and methylation analysis
Genomic DNA was extracted from subjects’ blood sampling. Methylation of 4 regions in SLC6A3 gene was assessed using bisulfite pyrosequencing. After bisulfite treatment of the DNA (EpiTect Fast DNA Bisulfite Kit, Qiagen, Hilden Germany), polymerase chain reaction test was done with DNA Engine Tetrad 2 Peltier Thermal Cycler (Bio-Rad, CA, USA). Primer Design was designed with PyroMark Assay Design 2.0 (Qiagen, Hilden Germany). Pyrosequencing was done with PyroMark Q48 Autoprep System (Qiagen, Hilden Germany). PyroMark Q48 Autoprep 2.4.2 Software (Qiagen, Hilden Germany) was used to assess methylation of each CpG site, 4 regions in SLC6A3 gene. The percentage of methylated alleles was divided by the total number of alleles (methylated and unmethylated) to determine the level of methylation at each CpG site. The mean percentage of methylation (%) for each cluster was calculated by taking the average of all CpG site methylation levels measured within the cluster.
Questionnaire
Subjects were assessed with GRAPES [14]. GRAPES consists of 30 items related with the reward and punishment that individuals expect for their behaviors, GRAPES (A) reward expectancy, GRAPES (B) punishment expectancy.
Anzeige
Statistical analysis
Normality was assessed using the D’Agostino & Pearson normality test. Spearman correlation test was done to determine the association of DAT methylation with BPNDs and GRAPES. As 4 clusters of DAT methylation were included in this study, significance was set at ɑ = 0.05/4 (0.0125) to correct for multiple comparisons. All analyses were conducted using Prism (v7.0d, GraphPad Software Inc, La Jolla, CA, USA).
Results
Thirty-five healthy males, with an age range between 20 and 30 years, and a mean age of 24.4 ± 2.7 years, were included in this study. Coordinates and the percentage of methylated alleles (%) for all SLC6A3 CpG sites are presented in Table 1. The mean percentages of methylation (%) were 9.9 (cluster A), 76.1 (cluster B), 91.6 (cluster C), 75.1% (cluster D), respectively. The mean percentage of methylation (%) from each cluster did not show any association each other (Fig. 1). The mean percentage of methylation (%) from each cluster was not associated with DAT availability of the ventral striatum, showing a trend of positive correlation between that from cluster C and DAT availability of the ventral striatum without correction (rho = 0.3712, p = 0.0281), which was not significant after correction for multiple comparison. In addition, the mean percentage of methylation (%) from cluster C was positively correlated with GRAPES A: reward expectancy scale (rho = 0.7178, p < 0.0001) (Figs. 2, 3).
Table 1
Coordinates and the percentage of methylated alleles (%) for all SLC6A3 CpG sites
Assay ID
CpG ID
Cluster
From ATG
From TSS
GRCh37/hg19
Region
The percentage of methylated alleles (%)
ADS2165RS2
237
A
− 3177
− 944
1446489
Promoter
13.43
ADS2165RS2
236
A
− 3174
− 941
1446486
Promoter
16.98
ADS2165RS2
235
A
− 3167
− 934
1446479
Promoter
9.30
ADS2165RS2
234
A
− 3163
− 930
1446475
Promoter
10.15
ADS2165RS2
233
A
− 3151
− 918
1446463
Promoter
6.03
ADS2165RS2
232
A
− 3148
− 915
1446460
Promoter
9.79
ADS2165RS1
231
A
− 3134
− 901
1446446
Promoter
8.85
ADS2165RS1
230
A
− 3132
− 899
1446444
Promoter
4.38
ADS2127FS
547
B
26,817
29,050
1416496
Intron 6
79.69
ADS2127FS
548
B
26,856
29,089
1416504
Intron 6
72.46
ADS2126FS2
551
C
27,008
29,241
1416305
Exon 7, Intron 6
95.82
ADS2126FS2
552
C
27,010
29,243
1416303
Exon 7, Intron 6
88.41
ADS2126FS
553
C
27,038
29,271
1416275
Exon 7, Intron 6
98.75
ADS2126FS
554
C
27,047
29,280
1416266
Exon 7, Intron 6
83.28
ADS2796FS1
1149
D
48,635
50,868
1394678
Exon 15 3’UTR
70.80
ADS2796FS1
1150
D
48,640
50,873
1394673
Exon 15 3’UTR
96.21
ADS2796FS1
1151
D
48,646
50,879
1394667
Exon 15 3’UTR
65.53
ADS2796FS1
1152
D
48,653
50,886
1394660
Exon 15 3’UTR
78.86
ADS2796FS1
1153
D
48,656
50,889
1394657
Exon 15 3’UTR
62.88
ADS2796FS2
1154
D
48,679
50,912
1394634
Exon 15 3’UTR
69.95
ADS2796FS2
1155
D
48,682
50,915
1394631
Exon 15 3’UTR
69.51
ADS2796FS2
1156
D
48,697
50,930
1394616
Exon 15 3’UTR
92.09
ADS2796FS2
1157
D
48,709
50,942
1394604
Exon 15 3’UTR
70.38
×
×
×
Discussion
In this study, the degrees of methylation from cluster C (Exon 7) of DAT in peripheral blood showed a trend of positive correlation with DAT availability of the ventral striatum and were significantly correlated with reward scales of GRAPES A: reward expectancy scale.
This is the first study that investigated the association between the degree of methylation of DAT and DAT availability of PET in healthy subjects. Previously, the association of methylation of DAT gene with DAT availability was investigated in patients with attention-deficit hyperactivity disorder (ADHD) [13], which is the only study of DAT methylation and PET. Although methylation of DAT gene was not significantly different between patients with ADHD and healthy subjects, DAT availability measured by 11C-cocaine PET was negatively correlated with the degree of DAT methylation in patients with ADHD, not in healthy subjects [13]. This correlation was significant in both caudate nucleus, putamen, and ventral striatum [13]. However, the underlying mechanisms of insignificancy between DAT availability and DAT methylation in healthy subjects remained unclear. In subjects with alcohol dependency, the effect of DAT methylation was investigated with reward processing [10] and depressive symptoms [17] using functional magnetic resonance imaging. DAT methylation in promoter region predicted activation of nucleus accumbens during the anticipation of high and low loss in healthy subjects, not in subjects with alcohol dependency [10]. In addition, subjects with alcohol dependency showed that activity of amygdala to alcohol cue was correlated with DAT methylation only those with low depression scores [17]. Also, higher DAT methylation predicted the relapse of alcohol dependency [17].
Epigenetic change is a heritable phenotype change without alterations in the DNA sequence, such as DNA methylation. DNA methylation is a process that adds methyl groups to cytosines of the genome, mostly in CpG sites [8]. DNA methylation inhibits gene expression by preventing transcription factors from binding to DNA [9]. Therefore, DNA methylation has shown to be inversely associated with protein expression [10]. In rodent, DAT methylation was negatively associated with striatal DAT expression [18]. In humans, only one study reported the association between DAT methylation and DAT availability measured by 11C-cocaine PET as explained above [13]. Inconsistent with the study by Wiers et al., we demonstrated a trend of positive association between DAT methylation and DAT availability measured by 18F-FP-CIT PET. In addition, the mean percentage of methylation (%) from cluster C was strongly correlated with GRAPES A: reward expectancy scale, similar to the study by Muench et al., which predicted striatal responses during reward processing by DAT methylation in healthy subjects, not in alcohol-dependent individuals [10]. DAT methylation in alcohol-dependent individuals [10], or ADHD [13], showed the difference with that in healthy subjects. Therefore, DAT methylation might have an implication on treatment of alcohol dependency or ADHD.
There are several points that should be considered in these results. First, it is unclear that whether DAT methylation obtained from peripheral blood has an association with DAT methylation of brain. In this regard, Wiers et al. proved the significant correlation between DAT methylation of substantia nigra and DAT methylation from peripheral blood both in healthy subjects and patients with ADHD, however, showing moderate correlation in both promotor region (r = 0.44), and CpG site 230 (r = 0.53) of healthy subjects [13]. Second, the mean percentage of methylation was calculated from each cluster and considered as the degree of DAT methylation level. However, the degree of DAT methylation may be different within each cluster, and the region of each cluster may be different. Third, the radiopharmaceuticals used in measurement of DAT availability were different in each study. Theoretically, as DNA methylation inhibits or regresses the binding of transcription factors [9], DNA methylation might be negatively associated with protein expression [10]. However, at least with regard to DAT, this association is unclear until now as we showed a trend of positive association between DAT methylation and DAT availability, and Wiers et al. showed no significant association [13]. The mechanisms underlying these findings might be complex and likely vary across genes. Also, as a small number of subjects were included in this study, further studies of a larger number of subjects with a broader age range should be carried out in the future.
Conclusion
DAT methylation from peripheral blood showed a trend of positive correlation with DAT availability of ventral striatum in healthy subjects; however, it was not significant after correction for multiple comparison. The degrees of methylation from cluster C of DAT in peripheral blood were significantly correlated with reward scales of GRAPES A: reward expectancy scale. The association between DAT methylation and DAT expression needs to be investigated further.
Declarations
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Ethical permission for the study procedures was obtained from the Institutional Review Boards at Pusan National University Hospital. Subject consent has been obtained by Pusan National University Hospital. This article does not contain any studies with animals performed by any of the authors.
Anzeige
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.